Oral and nasal administration of chicken type II collagen suppresses adjuvant arthritis in rats with intestinal lesions induced by meloxicam

Table 1 Effects of oral and nasal administration of CII on activities of intestinal MPO and DAO in AA rats with or without intragastrical administration of meloxicam (n = 12, mean ± SD)

Groups	DAO (A/mg pro)	MPO (ΔA/(min·g))
Nomal	0.37 ± 0.065	99.47 ± 22.54
AA model	0.26 ± 0.031b	139.80 ± 25.14
AA model + meloxicam	0.15 ± 0.032ab	165.42 ± 21.27b
AA model + oral CII	0.27 ± 0.051	137.15 ± 26.32
AA model + nasal CII	0.28 ± 0.029	132.17 ± 23.18
AA model + meloxicam + oral CII	0.15 ± 0.052ab	159.25 ± 33.36b
AA model + meloxicam + nasal CII	0.16 ± 0.029ab	152.29 ± 27.20b

^aP < 0.05 vs AA model;

^bP < 0.01 vs normal control.

Table 2 Effects of oral and nasal administration of CII on hind paw secondary swelling in AA rats with or without intragastrical administration of meloxicam (n = 12, mean ± SD)

Groups	Dose (μg/kg)	d 14	d 16	d 20	d 24	d 28
Normal	---	0.07 ± 0.05	0.12 ± 0.04	0.19 ± 0.04	0.23 ± 0.03	0.26 ± 0.03
AA model	---	0.41 ± 0.31d	0.63 ± 0.16d	0.99 ± 0.21d	1.22 ± 0.27d	1.16 ± 0.21d
AA model + meloxicam	---	0.29 ± 0.32a	0.45 ± 0.27a	0.68 ± 0.18ad	0.97 ± 0.49d	0.99 ± 0.32d
AA model + oral CII	20	0.39 ± 0.12	0.59 ± 0.27	0.97 ± 0.15	0.81 ± 0.17a	0.79 ± 0.21a
AA model + nasal CII	20	0.38 ± 0.12	0.63 ± 0.13	1.03 ± 0.10	0.69 ± 0.07b	0.48 ± 0.09bc
AA model l + meloxicam + oral CII	20	0.31 ± 0.09	0.46 ± 0.26	0.70 ± 0.12a	0.79 ± 0.31a	0.95 ± 0.25
AA model + meloxicam + nasal CII	20	0.32 ± 0.16	0.43 ± 0.19	0.73 ± 0.22a	0.61 ± 0.21b	0.57 ± 0.17be

^aP < 0.05 vs AA model;

^bP < 0.01 vs AA model;

^cP < 0.05 vs AA model + oral CII;

^dP < 0.01 vs normal control;

^eP < 0.05 vs AA model + meloxicam + oral CII.

Table 3 Effects of oral and nasal administration of CII on synoviocytes proliferation in AA rats with or without intragastrical administration of meloxicam (n = 12, mean ± SD)

Groups	Dose (µg/kg)	Synoviocytes proliferation (A490)
Nomal	-	0.27 ± 0.024
AA model	-	0.32 ± 0.045d
AA model + meloxicam	-	0.31 ± 0.025d
AA model + oral CII	20	0.27 ± 0.041b
AA model + nasal CII	20	0.24 ± 0.048b
AA model l + meloxicam + oral CII	20	0.29 ± 0.047a
AA model + meloxicam + nasal CII	20	0.25 ± 0.041bc

^aP < 0.05 vs AA model;

^bP < 0.01 vs AA model;

^dP < 0.01 vs normal control;

^cP < 0.05 vs AA model + meloxicam + oral CII.